“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910